Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

Completed · Phase 1

Conditions studied: Cancer

In brief

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Key facts

Study ID

NCT00506805

Run by

Esanex Inc.

People needed

44

Starts

2007-06-01

Expected to finish

2010-03-01

Last updated by the study team

2012-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• >18 years old
• histologically confirmed solid tumor malignancy
• refractory to available therapy or for which no therapy is available
• adequate organ function

You may not qualify if…

• CNS malignancy
• significant GI disease
• at risk for prolonged QT interval

Where it is running

• Pfizer Investigational Site — Scottsdale, Arizona, United States
• Pfizer Investigational Site — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.